Eledon Pharmaceuticals Inc ELDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
-
Eledon Shares Rise on Fast-Track Designation for Kidney Treatment
-
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
-
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
-
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
-
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Trading Information
- Previous Close Price
- $2.30
- Day Range
- $2.20–2.35
- 52-Week Range
- $1.35–4.60
- Bid/Ask
- $2.31 / $2.40
- Shares Outstanding
- 81.26M
- Market Cap
- $186.90M
- Volume/Avg
- 420,025 / 904,284
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.eledon.com
Valuation
|
Metric
|
ELDN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ELDN
Financial Strength
|
Metric
|
ELDN
|
|---|---|
Quick Ratio | 7.56 |
Current Ratio | 7.90 |
Interest Coverage | — |
Quick Ratio
ELDN
Profitability
|
Metric
|
ELDN
|
|---|---|
Return on Assets (Normalized) | −49.42% |
Return on Equity (Normalized) | −144.80% |
Return on Invested Capital (Normalized) | −142.94% |
Return on Assets
ELDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YXBk@>@ | LOCK|F@l# | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>%?XyMJ | LOCK|hm^@@ | $83B | |||
| Moderna Inc
MRNA
| LOCK|$xnv@# | LOCK|r! | $80B | |||
| argenx SE ADR
ARGX
| LOCK|SB&@%^ | LOCK|>&h | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v#NdJ^K | LOCK|B&@ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|snGP#>@ | LOCK|!F&< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jlPfkFQ | LOCK|FpTS | $28B | |||
| Incyte Corp
INCY
| LOCK|w&P?dt | LOCK|R^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|WYz@%k | LOCK|%JR | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|??qL##N | LOCK|p^s | $14B |
United States